-
1.发明申请公开(公告)号：US20190233466A1
公开(公告)日：2019-08-01
申请号：US16277861
申请日：2019-02-15
发明人： Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要： The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
公开(公告)号：US10208082B2
公开(公告)日：2019-02-19
申请号：US15510208
申请日：2015-09-09
发明人： Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要： The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
公开(公告)号：US10808006B2
公开(公告)日：2020-10-20
申请号：US16277861
申请日：2019-02-15
发明人： Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要： The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
4.发明申请公开(公告)号：US20170260228A1
公开(公告)日：2017-09-14
申请号：US15510208
申请日：2015-09-09
发明人： Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
CPC分类号： C07J71/001 , A61K9/0048 , A61K9/1647 , A61K9/204 , A61K31/58 , A61P27/02 , C07J63/008 , Y02A50/473
摘要： The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
-
-
搜索结果
4 条记录 (耗时 0.014 秒)
